Evidence map›Paper›PMID 39144624›Full record

ArticleFrontiers in pharmacology2024

Mild-moderate alcohol consumption and diabetes are associated with liver fibrosis in patients with biopsy-proven MASLD.

Ang Huang, Cailun Zou, Zhe Dai, Ying Sun, Jing Wang, Shuhong Liu, Lin Han, Songhai Chen, Qingsheng Liang, Chunyan Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ang Huang *Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Cailun Zou *Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, China.
Zhe Dai *School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Ying Sun *Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Jing Wang *Inner Mongolia Institute of Digestive Diseases, The Second Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China.
Shuhong LiuDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Lin HanDepartment of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Songhai ChenDepartment of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Qingsheng LiangDepartment of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Chunyan WangDepartment of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Yingjie ZhuangDepartment for Disease Control and Prevention, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Tong DangSchool of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Binxia ChangDepartment of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Yijin WangSchool of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Zhengsheng ZouDepartment of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It is unclear whether patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are allowed variable low levels of alcohol. This study aimed to evaluate the effect of mild-moderate alcohol consumption on the biochemical and histological characteristics of patients with MASLD. Methods: Alcohol consumption was assessed in 713 patients with steatotic liver disease (SLD) who underwent liver biopsy. Non-drinking, mild-moderate drinking, and excessive drinking were defined as 0 g/day, 1-<20 g/day, and >20 g/day for women and 0 g/day, 1-<30 g/day, and >30 g/day for men, respectively. Liver biopsies were scored according to the NASH CRN system. Results: A total of 713 participants (median age 39.0 years and 77.1% male) with biopsy-proven SLD were enrolled, including 239 nondrinkers, 269 mild-moderate drinkers and 205 excessive drinkers. Excessive drinking was associated with increased risks for lobular inflammation and liver fibrosis compared to nondrinkers and mild-moderate drinkers. Compared with non-drinkers, mild-moderate drinkers had significantly lower odds for steatosis (OR = 0.60, 95% CI = 0.38-0.93, Conclusions: Mild-moderate alcohol consumption might be protective against liver fibrosis in MASLD patients, which is modified by the presence of T2DM. However, further longitudinal studies are needed to determine the effect of ongoing alcohol consumption on disease severity.

Indexed as

fibrosis stageMASLD, metabolic dysfunction-associated steatotic liver diseasemild-moderate alcohol consumptionmultivariate logistic regressiontype 2 diabetes mellitus

Identifiers

PMID39144624
PMCPMC11322122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.